RxDoctor Payments Data

Kathryn Casull, MD

Internal Medicine · West Valley City, UTNPI 1831256635

Payments from drug & device makers

$4,396in general payments, 2019–2025

Across 266 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$539
  • Boehringer Ingelheim$490
  • Pfizer$369
  • GSK$263
  • Lilly USA, LLC$253
  • Astellas Pharma US Inc$246
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,376100%
  • Other$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,396 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$92,295
Medicare patients
205
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide88$110,626
OzempicSemaglutide77$97,221
TrulicityDulaglutide68$81,804
EliquisApixaban57$64,465
JardianceEmpagliflozin51$45,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$25,076
MyrbetriqMirabegron36$24,824
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$21,525
RybelsusSemaglutide17$21,496
FarxigaDapagliflozin Propanediol24$18,977
JanuviaSitagliptin Phosphate11$14,009
Spiriva RespimatTiotropium Bromide19$13,805
Tresiba Flextouch U-200Insulin Degludec13$12,501
BelsomraSuvorexant20$8,945
Breo ElliptaFluticasone/Vilanterol15$8,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$253$192,430156 claims
Novo NordiskOzempic, Rybelsus$222$118,71794 claims
PfizerEliquis$369$64,46557 claims
Boehringer IngelheimJardiance, Spiriva Respimat$490$59,12570 claims
GSKTrelegy Ellipta, Breo Ellipta$263$33,45350 claims
Astellas Pharma US IncMyrbetriq$246$24,82436 claims
MerckJanuvia, Belsomra$55$22,95431 claims
AstraZenecaFarxiga$71$18,97724 claims
Sanofi-aventis U.S. LLCLantus$176$3,68713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.

Other internal medicine in West Valley City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →